Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DELCATH SYSTEMS, INC.DCTH · Entity 5387 | SVP CLINICAL DEV & MED AFFAIRS | February 08, 2023 | January 26, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DELCATH SYSTEMS, INC.
Report date February 08, 2023 · Filed January 26, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.67 · Expires 2033-02-08 | Direct | 46,800 |
Reported balance
After 2023-02-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-08 · Grant · Acquired 46,800 · Balance 46,800 F1: The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 8, 2023 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions ofthe Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 8, 2023 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions ofthe Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2023 Filed Jun 22, 2023 01:16 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (Right to Buy) · Derivative | 59,813 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000899243-23-016193 · doc4.xml · derivative · entry 1 John Johnny · CIK 0001922221 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,813 Underlying: Common Stock · 59,813 shares Expires 2033-06-12 F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on July 12, 2023 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). Read SEC document |
| February 08, 2023 Filed Jan 26, 2024 21:22 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (Right to Buy) · Derivative | 46,800 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0001415889-24-001865 · form4-01262024_090115.xml · derivative · entry 1 John Johnny · CIK 0001922221 · SVP CLINICAL DEV & MED AFFAIRS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,800 Underlying: Common Stock · 46,800 shares Expires 2033-02-08 F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 8, 2023 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions ofthe Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.